Recent News

• 04.07.2025 - Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States
• 04.07.2025 - Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
• 03.31.2025 - New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable
• 03.27.2025 - Teva Releases Q1 2025 Aide Memoire
• 03.27.2025 - Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

Recent Filings

• 04.07.2025 - 3 Initial statement of beneficial ownership of securities
• 03.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.07.2025 - 4 Statement of changes in beneficial ownership of securities